Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
COMPARATIVE STUDY
Helen E Baxendale, Sheila M Keating, Marina Johnson, Jo Southern, Elizabeth Miller, David Goldblatt
In young children, polyvalent pneumococcal polysaccharide conjugate vaccines (PCVs) have been shown to offer advantage over plain polysaccharide vaccines (PPVs) in both immunogenicity and priming for memory responses. In the elderly, the potential benefit of conjugate vaccines is unclear. Here, we explore the early kinetics of serum antibody and circulating plasma and memory B cell responses to pneumococcal capsular polysaccharide (PPS) in older adults (n=37) immunised a PPV vaccine, Pneumovax or a PCV: Prevenar...
July 5, 2010: Vaccine
#2
RANDOMIZED CONTROLLED TRIAL
Isabel Leroux-Roels, Jeanne-Marie Devaster, Geert Leroux-Roels, Vincent Verlant, Isabelle Henckaerts, Philippe Moris, Philippe Hermand, Pascale Van Belle, Jan T Poolman, Pierre Vandepapelière, Yves Horsmans
BACKGROUND: The protection elicited by polysaccharide pneumococcal vaccines against community-acquired pneumonia in older adults remains debatable. Alternative vaccine targets include well-conserved pneumococcal protein antigens, such as pneumococcal histidine triad protein D (PhtD). OBJECTIVE: To evaluate humoral and cellular immune responses and safety/reactogenicity following immunisation with PhtD vaccine with or without adjuvant (alum or AS02V) in older (≥65 years) and young (18-45 years) healthy adults...
January 15, 2015: Vaccine
#3
RANDOMIZED CONTROLLED TRIAL
Mark T Dransfield, Sarah Harnden, Robert L Burton, Richard K Albert, William C Bailey, Richard Casaburi, John Connett, J Allen D Cooper, Gerard J Criner, Jeffrey L Curtis, Meilan K Han, Barry Make, Nathaniel Marchetti, Fernando J Martinez, Charlene McEvoy, Moon H Nahm, Dennis E Niewoehner, Janos Porszasz, John Reilly, Paul D Scanlon, Steven M Scharf, Frank C Sciurba, George R Washko, Prescott G Woodruff, Stephen C Lazarus
BACKGROUND: Although the 23-valent pneumococcal polysaccharide vaccine (PPSV23) protects against invasive disease in young healthy persons, randomized controlled trials in chronic obstructive pulmonary disease (COPD) have demonstrated no benefit in the intention-to-treat population. We previously reported that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) is safe and induced greater serotype-specific immunoglobulin G (IgG) and functional antibody than did PPSV23 1 month after vaccination...
September 2012: Clinical Infectious Diseases
#4
JOURNAL ARTICLE
Jae-Ouk Kim, Semi Rho, Su Hee Kim, Heejoo Kim, Hyo Jin Song, Eun Jin Kim, Ryang Yeo Kim, Eun Hye Kim, Anuradha Sinha, Ayan Dey, Jae Seung Yang, Man Ki Song, Ranjan Kumar Nandy, Cecil Czerkinsky, Dong Wook Kim
In developing countries, Shigella is a primary cause of diarrhea in infants and young children. Although antibiotic therapy is an effective treatment for shigellosis, therapeutic options are narrowing due to the emergence of antibiotic resistance. Thus, preventive vaccination could become the most efficacious approach for controlling shigellosis. We have identified several conserved protein antigens that are shared by multiple Shigella serotypes and species. Among these, one antigen induced cross-protection against experimental shigellosis, and we have named it pan-Shigella surface protein 1 (PSSP-1)...
April 2015: Clinical and Vaccine Immunology: CVI
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
